Radical prostatectomy is surgery to remove all of the prostate gland and some of the tissue around it, to treat prostate cancer.
UK doctors and surgeons have formulated what is probably the world's first clinical guidance on anal sex before, during, and after diagnosis and treatment for prostate cancer.
A specialized pain management program for patients who underwent robotic surgery for urologic cancers resulted in just eight percent going home with narcotics after discharge, compared to 100 percent who would have received them without this enhanced recovery protocol.
At a time when a growing number of men with prostate cancer considered "low risk" are opting for active surveillance or watchful waiting rather than immediate treatment with surgery or radiation, a new study reveals that black men are less likely than white men to adopt an active surveillance strategy for their disease.
For about 90 percent of men with prostate cancer, the cancer remains localized to the primary site, resulting in a five-year survival rate of almost 100 percent.
The American Society for Radiation Oncology and the American Urological Association today announced updates to their joint clinical guideline on adjuvant and salvage radiotherapy after prostatectomy in patients with and without evidence of prostate cancer recurrence to include new published research related to adjuvant radiotherapy.
Melbourne surgeons have modified a minimally invasive technique to help men regain erectile function lost after prostate cancer surgery.
Men who receive anti-hormonal treatment after having their prostate removed are 80% more likely to suffer from depression than men who don't receive this treatment. This leads researchers to suggest that patients receiving androgen deprivation therapy should be monitored for post-surgical depression.
In the largest such study so far undertaken, US researchers have shown that testosterone replacement slows the recurrence of prostate cancer in low-risk patients.
In 2010, the US National Comprehensive Cancer Network guidelines suggested that patients with stable and low-risk prostate cancers could be managed with active surveillance or watchful waiting (AS/WW). AS/WW was considered to be a safe and effective alternative to aggressive surgery to remove the prostate and radiation therapy.
The CMR high-tech surgical training facility is the first in the US to train surgeons with the next-generation robotic system, Versius.
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian men with prostate cancer for 29 years. The results are now published in The New England Journal of Medicine.
Interstitial brachytherapy uses slightly radioactive particles implanted into the prostate to deliver radiation directly to the tumour (low-dose-rate, LDR).
A small clinical trial using gold nanoparticles that act as tumor-seeking missiles on a mission to remove prostate cancer has begun at The University of Texas Health Science Center at Houston (UTHealth). It is the first trial of its kind in the world.
Three prominent medical societies today issued a new clinical guideline for physicians treating men with early-stage prostate cancer using external beam radiation therapy (EBRT). Adoption of the guideline could make treatment shorter and more convenient for many patients with prostate cancer, the most common malignancy among American men.
High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective than the other.
Researchers from the Keck School of Medicine of USC are looking to technology to help deconstruct expert surgeons' robotic surgery skills so they can create an objective, standardized way to train the next generation of surgeons.
Hackensack Meridian Health Bayshore Medical Center in Holmdel is now home to the da Vinci Si Surgical system, bringing advanced technology in surgery to the medical center's operating room and to the community.
Advanced Accelerator Applications S.A., a Novartis company and leader in nuclear medicine theragnostics, today announced that the first patients have been dosed in two Phase I/II clinical studies of radiolabeled PSMA-R2, a urea-based ligand of Prostate-Specific Membrane Antigen, which is commonly expressed on prostate cancer cells.
A new study reveals declines in prostate cancer screening and diagnoses in the United States in recent years, as well as decreases in the use of definitive treatments in men who have been diagnosed.
UCLA researchers have discovered that a combination of high doses of radiotherapy and hormonal therapy provides the best chance of decreasing the mortality rate in men with aggressive prostate cancer.